CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations

M. A. Province, M. P. Goetz, H. Brauch, D. A. Flockhart, J. M. Hebert, R. Whaley, V. J. Suman, W. Schroth, S. Winter, H. Zembutsu, T. Mushiroda, W. G. Newman, M. T M Lee, C. B. Ambrosone, M. W. Beckmann, J. Y. Choi, A. S. Dieudonné, P. A. Fasching, R. Ferraldeschi, L. GongE. Haschke-Becher, L. B. Jordan, U. Hamann, K. Kiyotani, P. Krippl, D. Lambrechts, A. Latif, U. Langsenlehner, W. Lorizio, P. Neven, A. T. Nguyen, B. W. Park, C. A. Purdie, P. Quinlan, W. Renner, M. Schmidt, M. Schwab, J. G. Shin, J. C. Stingl, P. Wegman, S. Wingren, A. H B Wu, E. Ziv, G. Zirpoli, A. M. Thompson, V. C. Jordan, Y. Nakamura, R. B. Altman, M. M. Ames, R. M. Weinshilboum, M. Eichelbaum, J. N. Ingle, T. E. Klein, Ute Hamann, Julia Boländer, Hans Ulrich Ulmer, Margarete Fischer-Bosch, Hiltrud Brauch, Werner Schroth, Matthias Schwab, Stefan Winter, Michel Eichelbaum, Peter Fritz, Wolfgang Simon, Julia C. Stingl, David A. Flockhart, Anne T. Nguyen, Jae Gook Shin, Ji Yeob Choi, Matthew P. Goetz, James N. Ingle, Vera J. Suman, Richard M. Weinshilboum, Colin A. Purdie, Lee B. Jordan, Pia Wegman, Hitoshi Zembutsu, Taisei Mushiroda, Kazuma Kiyotani, Christine B. Ambrosone, Peter A. Fasching, Reiner Strick, Matthias W. Beckmann, Patrick Neven, Anne Sophie Dieudonné, Elisabeth Haschke-Becher, Alan H B Wu, Wendy Lorizio, Elad Ziv, Philip Quinlan, Marcus Schmidt, Heinz Koelbl, William G. Newman, Roberta Ferraldeschi, Anthony Howell, Ayse Latif, Diether Lambrechts, Byeong Woo Park, Teri E. Klein, Ryan Whaley, Michael A. Province, Joan M. Hebert, Li Gong, Russ B. Altman, Christine A. Ambrosone, Alastair M. Thompson, Sten Wingren, Elad Ziv H

    Research output: Contribution to journalArticlepeer-review


    The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor-positive breast cancer, receiving 20 mg/day tamoxifen for 5 years, criterion 1); CYP2D6 poor metabolizer status was associated with poorer invasive disease-free survival (IDFS: hazard ratio = 1.25; 95% confidence interval = 1.06, 1.47; P = 0.009). However, CYP2D6 status was not statistically significant when tamoxifen duration, menopausal status, and annual follow-up were not specified (criterion 2, n = 2,443; P = 0.25) or when no exclusions were applied (criterion 3, n = 4,935; P = 0.38). Although CYP2D6 is a strong predictor of IDFS using strict inclusion criteria, because the results are not robust to inclusion criteria (these were not defined a priori), prospective studies are necessary to fully establish the value of CYP2D6 genotyping in tamoxifen therapy.
    Original languageEnglish
    Pages (from-to)216-227
    Number of pages11
    JournalClinical Pharmacology and Therapeutics
    Issue number2
    Publication statusPublished - Feb 2014


    Dive into the research topics of 'CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations'. Together they form a unique fingerprint.

    Cite this